Список литературы

1. Dummer R., Heald P.W., Nestle F.O. et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996; 88 (4): 1383 - 1389.

2. Campbell J.J., Clark R.A., Watanabe R., Kupper T.S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 116 (5): 767 - 771.

3. da Silva Almeida A.C., Abate F., Khiabanian H. et al. The mutational landscape of cutaneous T-cell lymphoma and Sezary syndrome. Nat Genet. 2015; 47 (12): 1465 - 1470.

4. Wang L., Ni X., Covington K.R. et al. Genomic profiling of Sezary syndrome identifies alterations of key T-cell signaling and differentiation genes. Nat Genet. 2015; 47 (12): 1426 - 1434.

5. Ungewickell A., Bhaduri A., Rios E. et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015; 47 (9): 1056 - 1060.

6. Berger C.L., Tigelaar R., Cohen J. et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005; 105 (4): 1640 - 1647.

7. Spicknall K.E. Sezary syndrome - clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37: 18 - 23.

8. Olsen E.A., Rook A.H., Zic J. et al. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011; 64 (2): 352 - 404.

9. Willemze R., Jaffe E.S., Burg G. et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105 (10): 3768 - 3785.

10. Kubica A.W., Davis M.D., Weaver A.L. et al. Sezary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol. 2012; 67 (6): 1189 - 1199.

11. Hristov A.C., Tejasvi T., Wilcox R.A. Mycosis fungoides and syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019; 94: 1027 - 1041.

12. Sentis H.J., Willemze R., Scheffer E. Histopathologic studies in Sezary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma. J Am Acad Dermatol. 1986; 15 (6): 1217 - 1226.

13. Trotter M.J., Whittaker S.J., Orchard G.E, Smith N.P. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol. 1997; 24 (5): 286 - 291.

14. Klemke C.D., Booken N., Weiss C. et al. Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol. 2015; 173 (1): 93 - 105.

15. Diwan A.H., Prieto V.G., Herling M. et al. Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol. 2005; 123 (4): 510 - 515.

16. Morice W.G., Katzmann J.A., Pittelkow M.R. et al. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol. 2006; 125 (3): 364 - 374.

17. Feng B., Jorgensen J.L., Jones D. et al. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sezary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol. 2010; 23 (2): 284 - 295.

18. Olsen E., Vonderheid E., Pimpinelli N. et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110 (6): 1713 - 1722.

19. Виноградова Ю.Е., Цыба Н.Н., Гилязитдинова Е.А. и др. Опыт лечения грибовидного микоза и синдрома Сезари в зависимости от стадий заболевания. Результаты собственных исследований и обзор литературы. Клиническая онкогематология 2009; 2 (4): 326 - 333.

20. Карамова А.Э., Чикин В.В., Знаменская Л.Ф., Воронцова А.А. T-клеточные лимфомы кожи: дифференциальная диагностика эритродермических состояний. Вестник дерматологии и венерологии. 2019; 95 (5): 24 - 32.

21. Ponti R., Quaglino P., Novelli M. et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol. 2005; 153 (3): 565 - 573.

22. Kirsch I.R., Watanabe R., O'Malley J.T. et al. TCR sequencing facilitates diagnosis and identifies mature T-cells as the cell of origin in CTCL. Sci Transl Med. 2015; 7 (308): 308ra158.

23. Vonderheid E.C. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol. 2006; 33 (Suppl 1): 27 - 42.

24. Mann B.S., Johnson J.R., Cohen M.H. et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12 (10): 1247 - 1252.

25. Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи: руководство для врачей. - М.: Практическая медицина, 2010. - 366 с.

26. Wallace C.A., Sherry D.D. A practical approach to avoidance of methotrexate toxicity [editorial] J Rheumatol. 1995; 22: 1009 - 1012.

27. Wood G.S., Wu J. Methotrexate and pralatrexate. Dermatol Clin. 2015; 33 (4): 747 - 755.

28. Busger op Vollenbroek F.T., Doggen C.J., Janssens R.W., Bernelot Moens H.J. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE 2018; 13 (3): e0194401.

29. Ahmadzadeh A., Zamani N., Hassanian-Moghaddam H. et al. Acute versus chronic methotrexate poisoning; a cross-sectional study. BMC Pharmacol Toxicol 2019; 20 (1): 39.

30. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311 - 321.

31. Kim Y.H., Tavallaee M., Sundram U. et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015; 33 (32): 3750 - 3758.

32. Talpur R., Singh L., Daulat S. et al. Long-term outcomes of 1,263 patients with mycosis fungoidesand syndrome from 1982 to 2009. Clin Cancer Res. 2012; 18 (18): 5051 - 5060.

33. Gobbi P.G., Broglia C., Carnevale Maffe G. et al. Lymphomatous superficial lymph nodes: limitations of physical examination for accurate staging and response assessment. Haematologica. 2002; 87 (11): 1151 - 1156.

34. Tsai E.Y., Taur A., Espinosa L. et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006; 142 (5): 577 - 584.

35. Toro J.R., Stoll H.L. Jr, Stomper P.C., Oseroff A.R. Prognostic factors and evaluation of mycosis fungoides and syndrome. J Am Acad Dermatol 1997; 37 (1): 58 - 67.

36. Trautinger F., Eder J., Assaf C. et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer. 2017; 77: 57 - 74.

37. Виноградова Ю.Е. Применение при T-клеточных лимфомах кожи. Гематология и трансфузиология 2012: 57 (3): 99 - 100.

38. Zackheim H.S. Epstein E.H. Jr. Low-dose methotrexate for the syndrome. J Am Acad Dermatol. 1989; 21 (4 Pt 1): 757 - 762.

39. Roenigk H.H. Jr, Kuzel T.M., Skoutelis A.P. et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95 (6 Suppl); 198S - 205S.

40. Kuzel T.M., Gilyon K., Springer E. et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82 (3); 203 - 207.

41. A., Nambo M.J., Neri N. et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/ syndrome. Cancer Biother Radiopharm 2007; 22 (6); 836 - 840.

42. Чернова Н.Г., Коломейцев О.А. Современные возможности оптимизации лечения грибовидного микоза и синдрома Сезари. Клиническая онкогематология. 2018; 11 (1): 34 - 41.

43. Photiou L., van der Weyden C., McCormack C., Prince H.M. Systemic treatment options for advanced-stage mycosis fungoides and syndrome. Curr Oncol Rep. 2018; 20 (4): 32.

44. Shiratori S., Fujimoto K., Nishimura M. et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol 2016; 34 (1): 9 - 16.

45. Wu P.A., Kim Y.H., Lavori P.W. et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant 2009; 15 (8): 982 - 990.

46. Virmani P., Zain J., Rosen S.T., Hematopoietic stem cell transplantation for mycosis fungoides and Sezary syndrome. Dermatol Clin 2015; 33: 807 - 818.

47. Lechowicz M.J., Lazarus H.M., Carreras J. et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 2014; 49 (11): 1360 - 1365.

48. Serrano L., Martinez-Escala M.E., Zhou X.A., Guitart J. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin 2018; 36: 245 - 258.

49. Schulz S., Metz M., Siepmann D. et al. Antipruritische Wirksamkeit einer hoch dosierten Antihistaminikatherapie. Hautarzt 2009; 60: 564 - 568.

50. Weisshaar E., Szepietowski J.C., Dalgard F.J. et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019; 99 (5): 469 - 506.

51. Левченко О.К. Опыт оказания противоболевой помощи в гематологическом стационаре. Российский журнал боли. 2019; 17 (1): 47 - 50.

52. Абузарова Г.Р., Невзорова Д.В., Кумирова Э.В. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва, 2016, 94 с.

53. Абузарова Г.Р. и др. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под редакцией И.В. Поддубной, В.Г. Савченко, 2018, С. 278 - 288.

54. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.